Kiadis Pharma NV has strengthened its scientific advisory board to guide the ongoing development of its cell therapy for patients who’ve had a stem cell transplant. This follows guidance from the European Medicines Agency that the product, ATIR101, will not be recommended for approval. ATIR101 has been under regulatory review since 2017.
